EGFR and carcinoma: In lung cancer, as well in other malignant carcinomas diseases, gene target-based therapies have emphasized the use of tyrosine kinase inhibitors (TKIs), focusing on a priority oncological gene target, the epidermal growth factor receptor (EGFR).